Expression of circadian rhythm gene Timeless in different parts of rectal cancer and its relationship with clinical characteristics and prognosis

doi:10.3877/cma.j.issn.1674-0793.2019.05.004

Abstract

Abstract:

Objective

To analyze the expression of biorhythmic gene Timeless in different parts of rectal cancer and their relationship with prognosis, so as to provide more possibilities for individualized treatment and prognosis monitoring.

Methods

From April 2012 to April 2015, 384 patients with rectal cancer admitted to Branch Courts of Huai’an First People’s Hospital were selected as source of specimens. According to the location of the tumors, they were divided into high group (n=64), middle group (n=122) and low group (n=198). The Real-time fluorescence quantitative PCR and immunohistochemistry were used to detect the expression of Timeless mRNA and protein in cancer tissues and adjacent normal tissues, and to analyze their relationship with clinical characteristics and survival.

Results

Timeless mRNA and protein in cancer tissues of high, middle and low rectal group were higher than those in normal adjacent tissues (P<0.01). The difference of Timeless mRNA and protein among the three groups was statistically significant (P<0.05), which was low group > middle group > high group. There were differences in tumor size, differentiation, TNM stage and survival in Timeless mRNA and protein. Cox regression analysis showed that tumor location, TNM stage and Timeless were independent risk factors for prognosis of rectal cancer (P<0.05).

Conclusion

Timeless is highly expressed in rectal cancer, especially in low rectal cancer, which is closely related to tumor size, differentiation, TNM stage and survival, and is one of the independent risk factors affecting its prognosis.

Key words: Rectal neoplasms, Circadian rhythm genes, Clinical characteristics, Prognosis

Jingsong Wang, Jianhuai Zhang, Hu Sun. Expression of circadian rhythm gene Timeless in different parts of rectal cancer and its relationship with clinical characteristics and prognosis[J]. Chinese Archives of General Surgery(Electronic Edition), 2019, 13(05): 350-353.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2019.05.004

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2019/V13/I05/350

Figures/Tables 4

References 15

[1]	杜灵彬，李辉章，王悠清，等. 2013年中国结直肠癌发病与死亡分析[J]. 中华肿瘤杂志, 2017, 36(9): 701-706.
[2]	郭雄图，陈显国，胡玉萍，等. 支链氨基酸转氨酶1高表达预测结直肠癌预后不佳的研究[J/CD]. 中华普通外科学文献（电子版）, 2017, 11(2): 89-92.
[3]	韩晶，张雪，张安度，等. 肿瘤部位对根治性切除术后不同分期结直肠癌患者预后的影响[J]. 中华外科杂志, 2018, 56(1): 68-73.
[4]	Chaix A, Zarrinpar A, Panda S, et al. The circadian coordination of cell biology[J]. J Cell Biol, 2016, 215(1): 15-25.
[5]	Maiese K. Moving to the rhythm with Clock (Circadian) genes, autophagy, mTOR, and SIRT1 in degenerative disease and cancer[J]. Curr Neurovasc Res, 2017, 14(3): 299-304.
[6]	Shostak A. Circadian clock, cell division, and cancer: from molecules to organism[J]. Int J Mol Sci, 2017, 18(4): 873-888.
[7]	Truong KK, Lam MT, Grandner MA, et al. Timing matters: circadian rhythm in sepsis, obstructive lung disease, obstructive sleep apnea, and cancer[J]. Ann Am Thorac Soc, 2016, 13(7): 1144-1154.
[8]	邹小明，李晓林. 结直肠癌的组学研究现状[J]. 中华实验外科杂志, 2016, 33(3): 557-560.
[9]	韩昌，刘冬良，周峰，等. 生物钟基因CLOCK蛋白对甲状腺乳头状癌的影响[J/CD]. 中华普通外科学文献（电子版）, 2016, 10(3): 179-182.
[10]	杨柳青，石汉平. 昼夜节律与肿瘤[J/CD]. 肿瘤代谢与营养电子杂志, 2017, 4(3): 338-342.
[11]	杨少芬，许鸣，杨海云，等. 生物节律基因NPAS2在结直肠癌组织中的表达及意义[J]. 南方医科大学学报, 2016, 36(5): 714-718.
[12]	宋何煜，张耀，江红. 生物节律基因Timeless的生物学功能研究进展[J]. 生物技术通讯, 2014, 25(3): 421-424.
[13]	Gadaleta MC, González-Medina A, Noguchi E. Timeless protection of telomeres[J]. Curr Genet, 2016, 62(4): 725-730.
[14]	Top D, Harms E, Syed S, et al. GSK-3 and CK2 kinases converge on Timeless to regulate the master clock[J]. Cell Rep, 2016, 16(2): 357-367.
[15]	Ozturk N, Ozturk D, Kavakli IH, et al. Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy[J]. Int J Mol Sci, 2017, 18(10): 314-333.

临床特点		例数	mRNA相对表达水平	t值	P值	蛋白IOD值	t值	P值
性别		?	?	1.190	0.235	?	1.291	0.298
?	男	249	2.94±0.45	?	?	10.67±1.37	?	?
?	女	135	2.88±0.51	?	?	10.86±1.39	?	?
年龄(岁)		?	?	0.570	0.569	?	0.199	0.842
?	<60	148	2.67±0.52	?	?	10.16±1.45	?	?
?	≥60	236	2.70±0.49	?	?	10.19±1.43	?	?
肿瘤大小(cm)		?	?	39.975	<0.01	?	36.115	<0.01
?	<5	276	1.48±0.27	?	?	7.06±1.13	?	?
?	≥5	108	3.05±0.49	?	?	13.48±2.34	?	?
分化情况		?	?	39.954	<0.01	?	11.822	<0.01
?	低	45	4.38±0.62	?	?	16.51±1.35	?	?
?	中-高	339	2.06±0.37	?	?	10.38±3.44	?	?
TNM分期		?	?	38.122	<0.01	?	24.361	<0.01
?	Ⅰ+Ⅱ	106	2.03±0.38	?	?	8.65±1.18	?	?
?	Ⅲ+Ⅳ	278	4.59±0.65	?	?	14.52±2.37	?	?
生存情况		?	?	24.405	<0.01	?	29.098	<0.01
?	是	260	2.69±0.61	?	?	6.51±1.33	?	?
?	否	124	4.14±0.37	?	?	13.95±3.56	?	?

临床特点		例数	mRNA相对表达水平	t值	P值	蛋白IOD值	t值	P值
性别		?	?	1.190	0.235	?	1.291	0.298
?	男	249	2.94±0.45	?	?	10.67±1.37	?	?
?	女	135	2.88±0.51	?	?	10.86±1.39	?	?
年龄(岁)		?	?	0.570	0.569	?	0.199	0.842
?	<60	148	2.67±0.52	?	?	10.16±1.45	?	?
?	≥60	236	2.70±0.49	?	?	10.19±1.43	?	?
肿瘤大小(cm)		?	?	39.975	<0.01	?	36.115	<0.01
?	<5	276	1.48±0.27	?	?	7.06±1.13	?	?
?	≥5	108	3.05±0.49	?	?	13.48±2.34	?	?
分化情况		?	?	39.954	<0.01	?	11.822	<0.01
?	低	45	4.38±0.62	?	?	16.51±1.35	?	?
?	中-高	339	2.06±0.37	?	?	10.38±3.44	?	?
TNM分期		?	?	38.122	<0.01	?	24.361	<0.01
?	Ⅰ+Ⅱ	106	2.03±0.38	?	?	8.65±1.18	?	?
?	Ⅲ+Ⅳ	278	4.59±0.65	?	?	14.52±2.37	?	?
生存情况		?	?	24.405	<0.01	?	29.098	<0.01
?	是	260	2.69±0.61	?	?	6.51±1.33	?	?
?	否	124	4.14±0.37	?	?	13.95±3.56	?	?

因素	β	SE	Wald	df	Sig.	Exp（β）	Exp（β）95%CI
肿瘤位置	0.429	0.118	5.134	1	0.014	1.581	1.029~2.720
肿瘤大小	0.624	0.292	4.307	1	0.081	1.220	0.864~1.675
分化情况	0.513	0.117	4.635	1	0.062	2.161	0.941~3.492
TNM分期	0.669	0.314	11.037	1	0.000	4.556	1.857~6.337
是否联合新辅助化疗	0.516	0.167	4.246	1	0.083	0.846	0.718~0.992
Timeless mRNA	0.603	0.224	8.923	-	0.002	1.046	1.018~1.073
Timeless蛋白	0.523	0.271	7.035	-	0.033	1.358	1.117~1.882

因素	β	SE	Wald	df	Sig.	Exp（β）	Exp（β）95%CI
肿瘤位置	0.429	0.118	5.134	1	0.014	1.581	1.029~2.720
肿瘤大小	0.624	0.292	4.307	1	0.081	1.220	0.864~1.675
分化情况	0.513	0.117	4.635	1	0.062	2.161	0.941~3.492
TNM分期	0.669	0.314	11.037	1	0.000	4.556	1.857~6.337
是否联合新辅助化疗	0.516	0.167	4.246	1	0.083	0.846	0.718~0.992
Timeless mRNA	0.603	0.224	8.923	-	0.002	1.046	1.018~1.073
Timeless蛋白	0.523	0.271	7.035	-	0.033	1.358	1.117~1.882

Please choose a citation manager

Content to export